Neurology · Greenville, SC
Neurology studies in Greenville, SC
10 recruiting studies have a site in Greenville.
10 recruiting studiesSource: ClinicalTrials.gov, refreshed October 26, 2026How we list studies
Studies
- RecruitingPhase 3
Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab
TG Therapeutics, Inc.
- Location
- Greenville, SC + 35 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 3
A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis
Zenas BioPharma (USA), LLC
- Location
- Greenville, SC + 24 other US sites
- Eligibility basics
- Ages 18–60
- RecruitingPhase 3
A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis
Zenas BioPharma (USA), LLC
- Location
- Greenville, SC + 18 other US sites
- Eligibility basics
- Ages 18–60
- RecruitingPhase 2
Strategy for Improving Stroke Treatment Response
Translational Sciences, Inc.
- Location
- Greenville, SC + 37 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
Novartis Pharmaceuticals
- Location
- Greenville, SC + 42 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 2/Phase 3
Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)
DiaMedica Therapeutics Inc
- Location
- Greenville, SC + 35 other US sites
- Eligibility basics
- Ages 18–90
- RecruitingPhase 3
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)
AbbVie
- Location
- Greenville, SC + 87 other US sites
- Eligibility basics
- Ages 6–17
- RecruitingPhase 3
Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.
Novartis Pharmaceuticals
- Location
- Greenville, SC + 42 other US sites
- Eligibility basics
- Ages 40–70
- RecruitingPhase 3
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
Eidos Therapeutics, a BridgeBio company
- Location
- Greenville, SC + 39 other US sites
- Eligibility basics
- Ages 18–75
- Recruiting
Early Feasibility Study (EFS) Evaluating Percutaneous Repair of the Atrial Septum With a Novel PFO Occluder: The PROTEA-PFO Study
Recross Cardio, Inc.
- Location
- Greenville, SC + 4 other US sites
- Eligibility basics
- Ages 18–65
Who these studies look for
Most require a confirmed diagnosis; memory studies often ask for a study partner who knows you well to attend some visits.
Matching a page like this one never means you qualify. Each research team decides eligibility at screening.